The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: Retrospective long-term follow-up

Takao, Toshiko; Ide, Takehiko; Yanagisawa, Hiroyuki; Kikuchi, Masatoshi; Kawazu, Shoji; Matsuyama, Yutaka

doi:10.1016/j.diabres.2010.03.027

Cited by 50 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of those studies that investigated the risk of retinopathy reported positive associations (4,6,7). An Italian population-based prospective cohort study also demonstrated a positive association between VVV in fasting glucose and all-cause mortality (24).…”

Section: Discussionmentioning

confidence: 99%

“…The outcomes studied in previous observational studies that assessed the effects of VVV in fasting glucose in patients with type 2 diabetes were retinopathy and mortality only (4)(5)(6)(7)24). Most of those studies that investigated the risk of retinopathy reported positive associations (4,6,7).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a number of studies have raised concerns about possible adverse effects of visit-to-visit glycemic variability in diabetes (4)(5)(6)(7)(8)(9)(10)(11)(12). Therefore, glycemic variability has the potential to provide additional value in the prediction of future complications in diabetes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

et al. 2014

View full text Add to dashboard Cite

OBJECTIVEThere is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA 1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial. RESEARCH DESIGN AND METHODSADVANCE was a factorial randomized controlled trial of intensive glucose control and blood pressure lowering in patients with type 2 diabetes. VVV in the intensive glucose treatment group was defined using the SD of five measurements of HbA 1c and glucose taken 3-24 months after randomization. Outcomes were combined macro-and microvascular events and all-cause mortality occurring post 24 months. Sensitivity analyses were performed using other indices of variability and in the standard glucose treatment group. RESULTSAmong 4,399 patients in the intensive group, an increase in VVV of HbA 1c was associated with an increased risk of vascular events (P = 0.01) and with mortality (P < 0.001): highest versus lowest tenth hazard ratio (95% CI) 1.64 (1.05-2.55) and 3.31 (1.57-6.98), respectively, after multivariable adjustment. A clear association was also observed between VVV of fasting glucose and increased risk of vascular events (P < 0.001; 2.70 [1.65-4.42]). HbA 1c variability was positively associated with the risk of macrovascular events (P = 0.02 for trend), whereas glucose variability was associated with both macro-and microvascular events (P = 0.005 and P < 0.001 for trend, respectively). Sensitivity analyses using other indices, and patients in the standard glucose treatment group, were broadly consistent with these results. CONCLUSIONSConsistency of glycemic control is important to reduce the risks of vascular events and death in type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

et al. 2014

View full text Add to dashboard Cite

show abstract

“…2 Clinically, glycemic variability was associated with greater mortality in intensive care, 3,5 increased rate of diabetes complications, 21 and postprandial beta-cell dysfunction. 22 However, data on the significance of glycemic variability is not as unequivocal as one could expect, with reports abolishing its importance altogether mixing with those in favor.…”

Section: Discussionmentioning

confidence: 99%

GlyCulator: A Glycemic Variability Calculation Tool for Continuous Glucose Monitoring Data

Czerwoniuk

Fendler

Walenciak

et al. 2011

J Diabetes Sci Technol

View full text Add to dashboard Cite

Abbreviations: (%CV) percentage coefficient of variation, (CGM) continuous glucose monitoring, (CONGA) continuous overall net glycemic action, (FD) fractal dimension, (HbA1c) glycated hemoglobin, (MAGE) mean amplitude of glycemic excursions, (MODD) mean of daily differences, (SD AbstractGlycemic variability has become a major concern over the years as growing evidence is gathered on its detrimental impact on the risk of diabetes complications. Glycated hemoglobin, although ubiquitous in clinical practice, does not adequately summarize short-term glycemic variability. This gap may be addressed through the use of continuous glucose monitoring, which continuously estimates glycemia based on interstitial fluid glucose concentration. As the amount of collected data is substantial, variability of the glycemic pattern can be analyzed in context of its direction, periodicity, and amplitude. As freely available variability calculation tools are limited in number and complexity, the authors have devised a simple-to-use Web-based application, "GlyCulator," allowing for rapid computation of glucose variability parameters from continuous glucose monitoring data.

show abstract

“…According to Takao et al [15] who investigated glycemic control over 10 years in Japanese type 2 diabetic patients, there was a correlation between the change of blood glucose and progression of diabetic retinopathy. In addition, Wadén et al [16] reported that HbA1c variability could not only predict incident microalbuminuria and progression of renal disease, but also cardiovascular events in type 1 diabetes patients.…”

Section: Discussionmentioning

confidence: 99%

Sitagliptin counteracts seasonal fluctuation of glycemic control

Matsuhashi

Sano²,

Fukuda³

et al. 2012

WJD

View full text Add to dashboard Cite

AIM:To assess the effect of sitagliptin therapy on seasonal fluctuation of glycemic control in Japanese type 2 diabetic patients. METHODS:Participating patients (age: 29-80 years) had been treated with conventional oral antidiabetic agents and/or diet and exercise therapy for over 6 mo. From December 2009, 35 patients were additionally prescribed oral sitagliptin starting from 50 mg once daily, while 19 patients taking α-glucosidase inhibitors were switched to sitagliptin. Twenty-four patients who refused sitagliptin formed the control group. Changes of mean monthly hemoglobin A1c (HbA1c) during the "winter holiday season" were compared between groups using Student's t -test (2008-2009 vs 2009-2010). Statistical significance was accepted at � < 0.05. �ulti�ariate 0.05. �ulti�ariate analysis was performed to assess whether sitagliptin use was associated with deterioration or improvement of glycemic control. RESULTS:Both add-on sitagliptin and switching from α-glucosidase inhibitors to sitagliptin prevented the seasonal deterioration of glycemic control and tended to improve HbA1c. Multivariate analysis revealed that both adding and switching to sitagliptin were negatively correlated with deterioration of glycemic control. In 44 patients who continued sitagliptin therapy for another year, elevation of HbA1c was suppressed without adverse effects. CONCLUSION:Sitagliptin is a suitable oral agent for preventing deterioration of glycemic control during the winter holiday season.

show abstract

The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: Retrospective long-term follow-up

Cited by 50 publications

References 20 publications

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

GlyCulator: A Glycemic Variability Calculation Tool for Continuous Glucose Monitoring Data

Sitagliptin counteracts seasonal fluctuation of glycemic control

Contact Info

Product

Resources

About